ARCHIVES

FDA Designates Zometa For Priority Review.

This article is from The Cancer Letter archive.

Vol. 27 No. 44 | November 30, 2001

Download PDF Visit The Full Archive

Related Articles

Denosumab Demonstrates Superiority Over Zometa For Bone Metastases

August 28, 2009

NCI appoints Robert Young chairman of the Board of Scientific Advisors, reappoints Ellen Sigal, and names 11 new members to board. Earnest Hawk to direct NCI Office of Centers, Training and Resources.

November 12, 2004

Budget Would Support 1,211 More Grants

February 7, 2003

Bristol To Support Grants For Studies On Drug Resistance

June 26, 1987

Chemoprevention Clinical Trials To starts In 1982 If Greenwald, DRCCA Board Can Move Fast Enough

August 28, 1981

Obey Questions NCI honesty, Transfers IARC Monograph Support To NIH

October 15, 1982